Company news
Todos Medical Ltd. (OTC:TOMDF) news
Todos Medical Ltd. news releases on 6ix. Latest, Dec 6, 2021: Todos Medical to Present at Upcoming Emerging Growth Conference
Press releases — page 3
Todos Medical to Present at Upcoming Emerging Growth Conference
December 6, 2021
Todos Medical Announces All 31 Patients Enrolled to Date in Tollovir® Phase 2 Clinical Trial in Hospitalized COVID-19 Patients Have Completed Study Participation
December 2, 2021
Todos Medical to Host Business Update Conference Call on December 2nd at 4:30 PM EST
December 1, 2021
Todos Medical Confirms SARS-CoV-2 PCR Test Kits Used at CLIA/CAP Lab Provista Diagnostics Detect Omicron Variant
November 30, 2021
Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma
November 29, 2021
DGAP-News: Todos Medical Announces Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. for Tollovid(R) Products Covering 30 Countries in Europe
November 23, 2021
Todos Medical Announces Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. for Tollovid® Products Covering 30 Countries in Europe
November 24, 2021
Todos Medical Receives Purchase Order for 50,000 Bottles of Tollovid Daily from Its European Distribution Partner T-Cell Protect Hellas S.A for Initial Market Launch in Greece
November 22, 2021
Todos Medical Announces Completion of Enrollment for COVID-19 Oral Antiviral 3CLPro (Mpro) Inhibitor Tollovir Phase 2 Clinical Trial Interim Analysis in Severe and Critical Hospitalized Patients
November 19, 2021
Todos Medical Announces Tollovid® Products Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. Covering 30 Countries in Europe
November 18, 2021
Todos Medical Announces Addition of Semi-Quantitative Titer Claims to the Emergency Use Authorization for the cPass Neutralizing Antibody Test
November 17, 2021
Update: Todos Medical Reports Third Quarter 2021 Business and Financial Results
November 16, 2021
Todos Medical’s Provista Laboratory to Boost Top Line Through New Atlanta-based Reference Lab Agreement for COVID PCR, cPass Neutralizing Antibody & Respiratory Pathogen Panel Tests
November 16, 2021
Todos Medical Reports Third Quarter 2021 Business and Financial Results
November 15, 2021
Todos Medical Sees Significant Ramp Up in COVID PCR Testing Volume at Its Provista CLIA/CAP Lab with New Automation in Place
November 2, 2021
Todos Medical Announces 2nd Clinical Trial Site for Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
November 1, 2021
Todos Medical to Present at the Benzinga Global Small Cap Conference
October 26, 2021
Todos Medical Announces Publication in Nature Neuroscience That Describes the Main Protease (3CL Protease) Causes Microvascular Brain Pathology
October 25, 2021
Todos Medical Announces Publication in Journal of Clinical Virology Highlighting Clinical Utility of cPass Semi-Quantitative Neutralizing Antibody Test in SARS-CoV-2 Risk Assessment Post-Vaccination or Recovery from Infection
October 21, 2021
Todos Medical to Conduct Webinar Highlighting the cPass SARS-COV-2 Neutralizing Antibody Test for AMDA, The Society for Post-Acute and Long-Term Care Medicine, on October 22, 2021 at 12:00 PM EDT
October 14, 2021
Todos Medical Announces Positive Data in Hospitalized and Outpatient Setting for TolloTest™, a Novel SARS-CoV-2 3CL Protease Biomarker Assay
October 6, 2021
UPDATE - Todos Medical Announces October Conference Calendar
October 5, 2021
Todos Medical Provides Update on COVID-19 Oral Antiviral 3CL Protease (Main Protease) Inhibitor Tollovir Clinical Development Program in Light of Molnupiravir Clinical Trial Data from Merck
October 4, 2021
Todos Medical Announces Positive Observational Trial Results for Oral Antiviral 3CL Protease (MPro) Inhibitor Tollovir®
September 30, 2021
Todos Medical Announces October Conference Calendar
September 28, 2021
Todos Medical Receives Approval by Amazon to Sell Immune Supplements Tollovid® & Tollovid Daily™
September 27, 2021
Todos Medical Reports Second Quarter 2021 Financial Results
September 24, 2021
UPDATE: Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders
September 24, 2021
Todos Medical Launches Tollovid Daily™ via Subscription at MyTollovid.com
September 23, 2021
Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Oral Antiviral Drug Candidate Tollovir™
September 20, 2021
Todos Medical Now Accepting Cryptocurrency for the Purchase of Tollovid® and Tollovid Daily™ Through Coinbase Commerce
September 17, 2021
Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders
September 15, 2021
CEO Presenting on the Emerging Growth Conference on September 15. Register Now
September 14, 2021
Todos Medical to Present at H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 (Virtual Conference)
September 13, 2021
Todos Medical’s CLIA/CAP Lab Provista Completes Validation of Combination COVID, Influenza A & B, RSV & hMPV Respiratory Panel Test
September 1, 2021
Todos Medical’s CLIA/CAP Lab Provista Completes Validation of High-Capacity SARS-CoV-2 Variant Testing Service Capable of Identifying Known Variants
August 26, 2021
Todos Medical’s CLIA/CAP Lab Provista Enters Into Reference Lab Agreement with Meadowlands Diagnostics to Provide cPass Neutralizing Antibody Blood Testing for Quantifying and Monitoring Key COVID-19 Immunity Biomarkers
August 24, 2021
Todos Medical Completes Validation of cPass Neutralizing Antibody Blood Test at Provista Diagnostics to Quantify and Monitor Key Biomarkers of COVID-19 Immunity
August 23, 2021
Todos Medical CEO to Appear on Fox Business Network Varney & Company Today at 11:40am to Discuss the Company’s Launch of cPass Neutralizing Antibody Testing for Monitoring COVID-19 Immunity
August 23, 2021
Todos to Present at Upcoming Emerging Growth Conference
August 17, 2021
CEO Presenting on the Emerging Growth Conference on August 18. Register Now
August 17, 2021
Update: Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Dietary Supplement Tollovid™
August 5, 2021
Todos Medical Receipt Notice of Allowance from USPTO for 3CL Protease Inhibitor Dietary Supplement Tollovid™
August 5, 2021
Todos Medical Makes Final Payment to Close Provista Diagnostics Acquisition
August 2, 2021
Todos Medical Retains CRO for COVID-19 Outpatient and Inpatient Phase 2/3 Clinical Trials for Oral Antiviral 3CL Protease Inhibitor Tollovir
July 28, 2021
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid Daily™ Including 3CL Protease Inhibitor Claim
July 22, 2021
Todos Medical to Launch EUA Authorized cPass SARS-CoV-2 Neutralizing Antibody Kit Through Agreement with Fosun Pharma
July 19, 2021
Todos Medical Appoints Ilanit Halperin, CPA as Corporate Controller
July 7, 2021
CEO Presenting on the Emerging Growth / Investors Hub Joint Conference on July 7. Register Now
July 6, 2021
Todos Medical Provides End of Second Quarter 2021 Corporate Update
June 29, 2021